Skip to main content
. 2020 Jul 1;24(4):363–372. doi: 10.4196/kjpp.2020.24.4.363

Fig. 7. Inhibition of interleukin-2 (IL-2) secretion by genipin in CD3/CD28 co-stimulated human T lymphocytes.

Fig. 7

(A) Human naïve CD4+ T lymphocytes were treated with different concentrations of genipin for 72 h; same volume of solvent (dimethyl sulfoxide, DMSO) under the same conditions was used as vehicle control. Cell viability was assessed with a CCK-8 assay. Cell viability of genipin-treated groups was assessed relative to that of control cells normalized as 1 (n = 3). (B) IL-2 levels were measured in culture supernatants of CD3/CD28 co-stimulated Jurkat T cells at 72 h post-treatment with 10 and 30 μM genipin; treatment with 10 μM BTP2 was used as a positive control. Significance of IL-2 secretion inhibition by genipin was compared between the genipin plus CD3/CD28 co-stimulation treatment group and the CD3/CD28 co-stimulation only group (n = 3). **p < 0.01, ****p < 0.0001 vs. the control.